title: Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model.
abstract: In this study, we investigated the in vivo efficacy of anidulafungin during the early phase of disseminated candidiasis in a neutropenic murine model and compared the results with those obtained for fluconazole. Antifungal efficacy was evaluated by reduction of fungal burden in the tissues of infected animals at periodic intervals during the first day of treatment. The fungal burden in tissues of drug-treated mice was reduced compared with controls in a time-dependent manner. At 24h after drug treatment, a >2 log(10) reduction of fungal burden in the kidney was obtained in the anidulafungin- and caspofungin-treated mice compared with a ca. 1.2 log(10) reduction in fluconazole-treated mice (P<0.003). There was no significant difference in the splenic fungal burden at 24h. Thus, echinocandins have excellent antifungal activity in the early phase of disseminated Candida albicans infection and may contribute to an improved outcome in critically ill immunocompromised/neutropenic patients.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI 48201, USA. skrishn@med.wayne.edu
authors.forename: Suganthini
authors.initials: S
authors.lastname: Krishnan-Natesan
authors.forename: Elias K
authors.initials: EK
authors.lastname: Manavathu
authors.forename: Jessica L
authors.initials: JL
authors.lastname: Cutright
authors.forename: Pranatharthi H
authors.initials: PH
authors.lastname: Chandrasekar
mesh_terms: D000077612:Anidulafungin; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D002176:Candida albicans / Q000187:drug effects / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy*; D000077336:Caspofungin; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D054714:Echinocandins / Q000627:therapeutic use*; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D007668:Kidney / Q000382:microbiology; D055666:Lipopeptides; D051379:Mice; D008813:Mice, Inbred ICR; D009503:Neutropenia / Q000150:complications*; D013154:Spleen / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D015725:Fluconazole; D000077612:Anidulafungin; D000077336:Caspofungin